NEW YORK (GenomeWeb) — Wells Fargo has downgraded Cepheid to Market Perform from Outperform, calling into question the company's "credibility and visibility" after it revised its 2017 profit outlook.

Cepheid reaffirmed its 2015 fourth quarter outlook at the Piper Jaffray Healthcare Conference on Tuesday, and also provided initial revenue guidance of $618 million to $635 million for Fiscal Year 2016. The company also updated its FY 2017 outlook to a gross margin of 56 percent to 58 percent, compared to its previous guidance of 60 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.